expand_moreexpand_lessexpand_moreexpand_less
|
 |
Sundeep GanoriaQuartz |
ABBV eyes a strong Q1 performance as neuroscience sales, led by Botox and Vraylar, are set to jump 22%, with newer drugs helping offset declines in...
ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under...
login
who are we?
contact us
qosheapp
